List of Excipients in Branded Drug ZOKINVY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sentynl Therapeutics Inc	ZOKINVY	lonafarnib	42358-450	CROSCARMELLOSE SODIUM	2027-11-20
Sentynl Therapeutics Inc	ZOKINVY	lonafarnib	42358-450	MAGNESIUM STEARATE	2027-11-20
Sentynl Therapeutics Inc	ZOKINVY	lonafarnib	42358-450	POLOXAMER 188	2027-11-20
Sentynl Therapeutics Inc	ZOKINVY	lonafarnib	42358-450	POVIDONE	2027-11-20

Zokinvy Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Zokinvy, the brand name for lonafarnib, is an oral farnesyltransferase inhibitor approved for Hutchinson-Gilford progeria syndrome and certain processing-deficient progeroid laminopathies. Its excipient strategy is conventional for hard capsules: lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and capsule-shell colorants. The larger commercial opportunity is not high-volume excipient substitution. It is development of pediatric-friendly dosage forms, food-compatible delivery systems, regional supply resilience, and differentiated formulations that preserve exposure in a very small patient population.

What excipients are used in Zokinvy capsules?

Zokinvy is supplied as 50 mg and 75 mg hard capsules. The FDA label identifies the capsule contents as containing lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The shell contains gelatin, titanium dioxide, and colorants. [1]

Component	Function	Commercial relevance
Lactose monohydrate	Diluent and bulk carrier	Creates a potential lactose-intolerance and excipient-sourcing consideration
Microcrystalline cellulose	Filler and compression or fill aid	Widely available and low regulatory risk
Croscarmellose sodium	Superdisintegrant	Supports rapid capsule-content dispersion
Magnesium stearate	Lubricant	Requires tight control of blending and lubrication
Gelatin	Capsule shell material	Creates animal-origin, dietary, and regional compliance considerations
Titanium dioxide and colorants	Capsule identification and appearance	Relevant to jurisdiction-specific colorant restrictions

Zokinvy capsules must be swallowed whole. Patients should not chew, crush, or open the capsules. The product is administered twice daily with morning and evening meals, and the label requires administration with food. [1]

What formulation properties determine Zokinvy excipient strategy?

The central formulation constraint is exposure. Lonafarnib is administered with food, and the product’s clinical use depends on consistent dosing around meals. An excipient change that alters dissolution, intestinal transit, or food interaction could affect systemic exposure and tolerability.

The current capsule platform has four practical characteristics:

1. It is familiar to regulators and manufacturers.
2. It is suitable for oral solid-dose production.
3. It is difficult for young children who cannot swallow capsules.
4. It limits flexibility for patients requiring altered administration.

The label also identifies gastrointestinal adverse reactions, including nausea, vomiting, diarrhea, and abdominal pain. [1] Excipients that improve capsule disintegration, reduce local irritation, or support lower-volume dosing could have commercial value, but any change would require comparative bioavailability and clinical justification.

What pediatric excipient opportunities exist for Zokinvy?

The strongest opportunity is a pediatric dosage form that avoids swallowing an intact capsule.

Sprinkle capsule

A modified capsule could contain coated lonafarnib multiparticulates that are sprinkled onto a soft food vehicle. This approach could preserve solid-state stability while improving administration for children. The formulation would need to address:

• Dose uniformity across a partial serving
• Protection from chewing
• Stability after opening
• Taste and mouthfeel
• Food compatibility
• Recovery of the full dose from the administration vehicle

A sprinkle product would not be a routine reformulation. If the current label prohibits opening the capsules, a new dosage form would require new product characterization and likely a supplemental NDA or separate NDA pathway.

Oral suspension

A liquid suspension could expand access to younger patients and patients with swallowing impairment. The principal formulation challenges are low aqueous solubility, sedimentation, chemical stability, preservative selection, microbial control, and taste masking.

Potential excipient categories include:

• Suspending polymers
• Wetting agents
• Buffer systems
• Preservatives
• Sweeteners and flavors
• Taste-masking polymers
• Antioxidants, if supported by degradation data

A suspension would have to demonstrate dose accuracy across the bottle, compatibility with dosing syringes, and stability under expected storage and in-use conditions. A liquid product could also create a new supply chain involving bottles, adapters, syringes, and refrigerated or controlled-temperature distribution.

Orally disintegrating or mini-tablet formats

Mini-tablets or orally disintegrating tablets could address patients who cannot swallow capsules but can accept a solid dosage form. Their value would depend on achieving dose flexibility across a wide pediatric weight range. The development burden would include taste masking, dose proportionality, mechanical robustness, and control of rapid disintegration without compromising absorption.

What patents protect Zokinvy formulations and delivery systems?

Zokinvy is a small-molecule drug, not a biologic. Patent risk therefore centers on compound, formulation, dosage regimen, manufacturing, and method-of-use claims rather than biosimilar substitution.

The relevant protection categories are:

Protection category	Relevance to Zokinvy
Lonafarnib compound patents	May cover the active ingredient or related farnesyltransferase inhibitors
Salt, polymorph, or solid-state patents	Could restrict alternative crystalline or amorphous forms
Capsule formulation patents	Could cover excipient ratios, dissolution, or release characteristics
Pediatric delivery patents	Could protect suspensions, sprinkle particles, mini-tablets, or taste masking
Method-of-use patents	Could cover progeria, laminopathy, dosing, or treatment combinations
Manufacturing patents	Could cover crystallization, purification, particle engineering, or scale-up

No commercial formulation strategy should assume that an excipient substitution avoids patent exposure. A new excipient system can still infringe claims directed to the dosage form, particle architecture, dissolution profile, administration method, or therapeutic use.

The FDA Orange Book listing for NDA 213969 is the relevant source for patents submitted as covering the approved product. [2] Patent searches should also include the USPTO and international equivalents because pediatric formulations and manufacturing processes may be protected outside the Orange Book.

When does Zokinvy lose exclusivity?

Zokinvy received FDA orphan-drug approval in November 2020 for its approved indications. Orphan-drug exclusivity generally lasts seven years from approval, subject to statutory exceptions. On that basis, the principal U.S. orphan exclusivity period runs into November 2027. [3]

Milestone	Date or status
FDA approval	November 2020
Regulatory pathway	New drug application
Orphan designation	Yes
Core orphan exclusivity period	Approximately seven years from approval
Expected end of principal orphan period	November 2027, subject to statutory treatment of the exclusivity period
Generic pathway after exclusivity	ANDA, if applicable
Biosimilar pathway	Not applicable

Patent expiry may extend beyond orphan exclusivity. A generic applicant could challenge listed patents through Paragraph IV certification before patent expiry. Approval and commercial launch would still depend on the applicant’s patent position, regulatory exclusivity, settlement terms, and any court-imposed restrictions.

What generic entry risks exist for Zokinvy?

Generic entry risk is structurally lower than for a mass-market medicine because the indication is ultra-rare, the patient population is small, and treatment requires specialty distribution and clinical familiarity. The risk is not zero.

A generic company would evaluate:

• Annual treatment revenue
• Patient identification and diagnosis rates
• Required pediatric dose ranges
• Manufacturing cost for low-volume production
• Orphan exclusivity timing
• Orange Book patents
• Clinical need for multiple strengths
• Reimbursement and specialty-pharmacy access
• Whether a capsule-only product is commercially sufficient

A first generic could seek approval for the same capsule strengths. A later entrant could pursue a lower-cost alternative, but the market may not support many competitors because development, pharmacovigilance, inventory, and distribution costs are high relative to patient volume.

A liquid or sprinkle formulation could create a separate competitive position. It might be protected by formulation patents, pediatric exclusivity, or regulatory differentiation even if the underlying lonafarnib compound is no longer protected.

Does Zokinvy face biosimilar competition?

No. Zokinvy contains lonafarnib, a chemically synthesized small molecule. FDA biosimilar rules apply to biological products, not conventional small-molecule capsules. Any follow-on product would generally proceed through the generic-drug framework, including an ANDA where the applicant can demonstrate pharmaceutical equivalence and bioequivalence. [4]

What FDA regulatory opportunities exist for new Zokinvy formulations?

A new dosage form could be pursued through several regulatory strategies:

Supplemental NDA

A sponsor holding the approved NDA could submit a supplemental application for a new strength, dosage form, manufacturing process, or administration method. This route benefits from reliance on the existing clinical and safety database, although new formulation-specific studies would remain necessary.

Separate NDA

A third party developing a differentiated pediatric product may require a separate NDA. The strategy would be more expensive but could support independent formulation patents, exclusivity, and commercial positioning.

Orphan-drug incentives

Orphan-drug programs can provide market exclusivity, tax incentives, fee benefits, and protocol assistance, subject to statutory eligibility and product-indication requirements. A new formulation does not automatically receive a new seven-year exclusivity period. The product must satisfy the applicable orphan-drug rules, including whether it is the same drug for the same use and whether clinical superiority is established where required. [3]

505(b)(2) considerations

A reformulated lonafarnib product could potentially be evaluated under a 505(b)(2) strategy if it relies partly on FDA findings for an approved product while introducing a new dosage form or route-related feature. The exact pathway would depend on the formulation, sponsor rights, referenced product, and required clinical evidence.

What commercial opportunities exist for excipient suppliers and CDMOs?

The commercial opportunity is concentrated in specialized development rather than bulk excipient volume.

High-value opportunities

• Pediatric suspension development
• Taste-masked lonafarnib multiparticulates
• Sprinkle capsules for children
• Low-volume mini-tablets
• Lactose-free or gelatin-free capsule alternatives
• Excipient systems that improve dose uniformity
• Packaging and dosing systems for ultra-rare pediatric drugs
• Stability-indicating formulation development
• Small-batch GMP manufacturing
• Regional supply of capsule shells and critical excipients

A supplier with a ready-to-use pediatric platform could reduce development time. The strongest value proposition would combine formulation know-how, analytical methods, pediatric administration data, and regulatory support.

Lower-value opportunities

Routine substitution of lactose, microcrystalline cellulose, or magnesium stearate is less attractive. These materials are widely available, and a substitution would create comparability, stability, dissolution, and regulatory work without necessarily improving patient outcomes.

How strong is the Zokinvy formulation and commercial estate?

The estate is commercially strong in indication specificity and clinical differentiation but narrower than the estate of a mass-market chronic therapy.

Factor	Assessment
Patient need	High
Market size	Very small
Generic economics	Limited but potentially attractive for a first entrant
Formulation differentiation	Significant opportunity in pediatric delivery
Biosimilar risk	None
Excipient substitution value	Moderate to low unless it solves administration or tolerability problems
Manufacturing complexity	Manageable for capsules; higher for stable pediatric liquids
Regulatory leverage	Strong orphan-drug context, but exclusivity is time-limited
Licensing value	Highest for pediatric formulations and geographic commercialization

Licensing transactions would likely focus on regional rights, specialty distribution, pediatric formulation technology, or manufacturing support. A global licensing deal for a conventional capsule-only product would be less compelling than a transaction involving a differentiated dosage form.

What patent litigation and settlement issues affect Zokinvy?

Potential litigation would most likely arise from:

• Paragraph IV challenges to Orange Book-listed patents
• Disputes over compound or formulation claims
• Method-of-use claims for progeria or laminopathies
• Patent term adjustment or patent term extension
• Settlement agreements governing generic launch
• Ownership disputes involving legacy development patents

A settlement could permit an authorized generic or delayed generic entry before the latest patent expiry. The economic effect would depend on the launch date, royalty structure, supply agreement, and whether the generic receives a 180-day exclusivity position.

Key Takeaways

• Zokinvy uses a conventional hard-capsule excipient platform based on lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, and colorants.
• The principal commercial gap is pediatric administration, not basic capsule manufacture.
• Sprinkle capsules, stable oral suspensions, and mini-tablets offer the clearest formulation opportunities.
• Zokinvy’s November 2020 approval created orphan-drug exclusivity extending approximately into November 2027.
• Biosimilar competition does not apply because lonafarnib is a small molecule.
• Generic risk is limited by the ultra-rare market, but a first ANDA entrant could still create material pricing pressure.
• Excipient suppliers and CDMOs have the greatest opportunity in pediatric delivery, taste masking, stability, and small-batch GMP manufacturing.
• Any reformulation must be screened against Orange Book patents, broader formulation claims, method-of-use claims, and international rights.

FAQs

Can Zokinvy capsules be opened and mixed with food?

The FDA label instructs patients to swallow Zokinvy capsules whole and not chew, crush, or open them. [1]

Is lactose-free Zokinvy a commercially attractive opportunity?

It could be attractive if a lactose-free formulation improves tolerability or broadens use in sensitive pediatric patients. The opportunity is stronger when combined with a new administration format, such as a sprinkle capsule or suspension.

Could an oral liquid create new Zokinvy exclusivity?

A liquid formulation could support formulation patents and, in some circumstances, regulatory exclusivity. It would not automatically receive a new seven-year orphan exclusivity period.

What is the most important excipient risk in a Zokinvy suspension?

The main risk is maintaining dose uniformity and chemical stability while controlling taste, sedimentation, microbial growth, and in-use shelf life.

Would a generic Zokinvy need to use the same excipients?

No. An ANDA applicant generally must demonstrate pharmaceutical equivalence and bioequivalence, but it may use different inactive ingredients subject to FDA safety, quality, and regulatory requirements. [4]

References

1. U.S. Food and Drug Administration. (2020). Zokinvy (lonafarnib) prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity. FDA.
4. U.S. Food and Drug Administration. (2014). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant DNA origin. FDA.